BioMarker Strategies® is a tissue-based cancer diagnostics company that is developing the SnapPath® live tumor cell testing platform* to improve the treatment of cancer.
Supported with funding from the National Cancer Institute, the SnapPath® platform enables the development of PathMap™ profiles which help guide targeted drug treatment selection, including drug combinations.
SnapPath units are being utilized in human clinical and preclinical studies for advanced melanoma and other solid tumors.
15601 Crabbs Branch Way
Rockville, MD 20855
*For Research Use Only (RUO).
in diagnostic procedures.